| Literature DB >> 33709571 |
Mu-Zi Yang1,2, Ren-Chun Lai2,3, Abbas E Abbas4, Bernard J Park5, Ji-Bin Li2,6, Jie Yang1,2, Jin-Chun Wu7, Gang Wang8, Hao-Xian Yang1,2.
Abstract
BACKGROUND: We aim to assess the learning curve of robotic portal lobectomy with four arms (RPL-4) in patients with pulmonary neoplasms using prospectively collected data.Entities:
Keywords: learning curve; lung neoplasm; robotic surgery
Mesh:
Year: 2021 PMID: 33709571 PMCID: PMC8088972 DOI: 10.1111/1759-7714.13927
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.500
FIGURE 1Incision strategy of RPL‐4 for lung neoplasm in each lobe. (a) Left upper lobe tumor, (b) right upper or middle lobe tumor, (c) left lower lobe tumor, and (d) right lower lobe tumor. Numbers 1, 2, and 3 represent robot arms. C, camera port; a, assistant's port
Patient characteristics of entire cohort (N = 100)
| Characteristics | Number of patients (%) |
|---|---|
| Tumor location | |
| RUL | 37 (37.0) |
| RML | 13 (13.0) |
| RLL | 16 (16.0) |
| LUL | 20 (20.0) |
| LLL | 24 (24.0) |
| Gender | |
| Male | 48 (48.0) |
| Female | 52 (52.0) |
| Age (years) | |
| Mean ± SD | 56.8 ± 11.1 |
| Median (min, max) | 59.0 (28, 79) |
| Tumor size (cm) | |
| Mean ± SD | 2.3 ± 1.0 |
| Median (min, max) | 2.2 (0.7, 7.2) |
| Smoking history | |
| Current | 18 (18.0) |
| Quit | 11 (11.0) |
| Never | 71 (71.0) |
| Neoadjuvant therapy | |
| Yes | 5 (5.0) |
| No | 95 (95.0) |
| Comorbidity | |
| No | 68 (68.0) |
| Yes | 32 (32.0) |
| Anatomical type | |
| Central | 1 (1.0) |
| Peripheral | 99 (99.0) |
| Histology | |
| Adenocarcinoma | 75 (75.0) |
| Squamous cell carcinoma | 5 (5.0) |
| Inflammation | 7 (7.0) |
| Tuberculosis | 2 (2.0) |
| Fungal infection | 4 (4.0) |
| Hamartoma | 1 (1.0) |
| Neuroendocrine carcinoma | 4 (4.0) |
| Pulmonary sclerosing haemangioma | 1 (1.0) |
| Inflammatory myofibroblastic tumor | 1 (1.0) |
| Clinical stage | |
| I | 85 (85.0) |
| II | 5 (5.0) |
| III | 8 (8.0) |
| IV | 2 (2.0) |
| Pathological stage | |
| I | 63 (75.0) |
| II | 5 (6.0) |
| III | 13 (15.5) |
| IV | 3 (3.6) |
| Operative time (min) | 130.6 ± 53.8 |
| Console time (min) | 95.5 ± 52.3 |
| Docking time (min) | 6.4 ± 3.0 |
| No. of mediastinal LNs harvested | 17.8 ± 13.5 |
| No. of total LNs harvested | 34.5 ± 18.4 |
| Blood loss (mL) | 116.1 ± 200.9 |
| Cost (¥) | 106234.59 ± 11859.46 |
Abbreviations: LLL, left lower lobe; LNs, lymph nodes.; LUL, left upper lobe; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe; SD, standard deviation.
Two cases with solitary brain metastasis received brain irradiation before lobectomy.
Excluded cases with benign lesions.
Two cases with solitary brain metastasis received brain irradiation before lobectomy. Pleural dissemination was found during surgery in one case.
Defined as the time of skin to skin. Patients with conversion were excluded.
Defined as the time of operating console. Patients converted to open surgery were excluded.
FIGURE 2Learning curve based on total operative time fit by fifth‐order regression using cumulative sum (CUSUM) analysis identifying three distinct phases (excluded five cases with conversion)
FIGURE 3Learning curve based on console time fit by sixth‐order regression using cumulative sum (CUSUM) analysis identifying three distinct phases (excluded five cases with conversion)
Univariate and multivariate analyses of the risk factors for robotic lobectomy failure (N = 100)
| Characteristics | Success ( | Failure | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
|
| B | OR |
| |||
| Sex | 0.844 | |||||
| Male | 35 | 13 | ||||
| Female | 37 | 15 | ||||
| Age (years) | 0.477 | |||||
| ≤ 60 | 42 | 14 | 0.451 | |||
| > 60 | 30 | 14 | ||||
| Smoking history | 0.953 | |||||
| Never | 51 | 20 | ||||
| Quit/current | 21 | 8 | ||||
| Tumor location | 0.771 | |||||
| RUL | 28 | 9 | ||||
| RML | 10 | 3 | ||||
| RLL | 11 | 5 | ||||
| LUL | 13 | 7 | ||||
| LLL | 10 | 4 | ||||
| Tumor size (cm) | 2.3 ± 1.1 | 2.3 ± 1.0 | 0.927 | |||
| Clinical stage | 0.417 | |||||
| I | 63 | 22 | ||||
| II | 3 | 2 | ||||
| III | 5 | 3 | ||||
| IV | 1 | 1 | ||||
| Comorbidity | 0.985 | |||||
| No | 49 | 19 | ||||
| Yes | 23 | 9 | ||||
| Histology | 0.552 | |||||
| Benign | 59 | 25 | ||||
| Malignant | 13 | 3 | ||||
| Blood loss (ml) | 50 (50.0, 60.0) | 100 (62.5, 300.0) | <0.001 | 0.021 | 1.021 | 0.001 |
| No. of mediastinal LNs harvested | 17.7 ± 13.1 | 18.1 ± 14.9 | 0.923 | |||
| Constant | −2.864 | 0.057 | <0.001 | |||
Abbreviations: LLL, left lower lobe; LNs, lymph nodes.; LUL, left upper lobe; OR, odds ratio; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe.
Surgical failure was defined as any of following events: conversion to open, perioperative complications, and operative time >180 min.
Two cases with solitary brain metastasis received brain irradiation before lobectomy.
FIGURE 4Risk‐adjusted cumulative sum (RA‐CUSUM) curve for the surgical failure of robotic lobectomy fit by sixth‐order regression
Comparison of clinicopathologic characteristics between different phases, N = 95 (%)
| Characteristics | Phase 1 ( | Phase 2 ( | Phase 3 ( |
|
|---|---|---|---|---|
| Tumor location | 0.055 | |||
| RUL | 1 (10.0) | 16 (39.0) | 18 (40.9) | |
| RML | 1 (10.0) | 9 (22.0) | 3 (6.8) | |
| RLL | 2 (20.0) | 7 (17.1) | 7 (15.9) | |
| LUL | 5 (50.0) | 3 (7.3) | 9 (20.5) | |
| LLL | 1 (10.0) | 6 (14.6) | 7 (15.9) | |
| Gender | 0.939 | |||
| Male | 5 (50.0) | 20 (48.8) | 20 (45.5) | |
| Female | 5 (50.0) | 21 (51.2) | 24 (54.5) | |
| Smoking history | 0.226 | |||
| Current | 1 (10.0) | 5 (12.2) | 11 (25.0) | |
| Quit | 2 (20.0) | 3 (7.3) | 5 (11.4) | |
| Never | 7 (70.0) | 33 (80.5) | 28 (63.6) | |
| Neoadjuvant therapy | 1.000 | |||
| Yes | 0 | 1 (2.4) | 4 (9.1) | |
| No | 10 (100.0) | 40 (97.6) | 40 (90.9) | |
| Comorbidity | 0.773 | |||
| No | 7 (70.0) | 26 (63.4) | 31 (70.5) | |
| Yes | 3 (30.0) | 15 (36.6) | 13 (29.5) | |
| Age (years) | 52.9 ± 14.2 | 59.6 ± 10.1 | 54.3 ± 10.7 | 0.050 |
| Tumor size (cm) | 2.8 ± 1.7 | 2.2 ± 1.1 | 2.2 ± 0.8 | 0.482 |
| Anatomical type | 1.000 | |||
| Central | 0 | 1 (2.4) | 0 | |
| Peripheral | 10 (100.0) | 40 (97.6) | 44 (100.0) | |
| Histology | 0.068 | |||
| Adenocarcinoma | 5 (50.0) | 31 (75.6) | 37 (84.1) | |
| Squamous cell carcinoma | 1 (10.0) | 2 (4.9) | 1 (2.3) | |
| Inflammation | 0 | 5 (12.2) | 2 (4.5) | |
| Tuberculosis | 1 (10.0) | 0 | 1 (2.3) | |
| Fungal infection | 1 (10.0) | 1 (2.4) | 2 (4.5) | |
| Hamartoma | 0 | 1 (2.4) | 0 | |
| Neuroendocrine carcinoma | 1 (10.0) | 0 | 1 (2.3) | |
| Pulmonary sclerosing haemangioma | 0 | 1 (2.4) | 0 | |
| Inflammatory myofibroblastic tumor | 1 (10.0) | 0 | 0 | |
| Clinical stage | 0.827 | |||
| I | 8 (80.0) | 35 (87.5) | 38 (86.4) | |
| II | 0 | 3 (7.5) | 2 (4.5) | |
| III | 2 (20.0) | 2 (5.0) | 3 (6.8) | |
| IV | 0 | 0 | 1 (2.3) | |
| Pathological stage | 0.245 | |||
| I | 7 (100.0) | 23 (69.7) | 29 (74.4) | |
| II | 0 | 4 (12.1) | 1 (2.6) | |
| III | 0 | 4 (12.1) | 8 (20.5) | |
| IV | 0 | 2 (6.1) | 1 (2.6) | |
| Pathological T category | 0.548 | |||
| T1 | 4 (57.1) | 24 (72.7) | 30 (76.9) | |
| T2 | 3 (42.9) | 8 (24.2) | 8 (20.5) | |
| T3 | 0 | 1 (3.0) | 1 (2.6) | |
| T4 | 0 | 0 | 0 | |
| Pathological N category | 0.346 | |||
| N0 | 7 (100.0) | 25 (75.8) | 30 (76.9) | |
| N1 | 0 | 4 (12.1) | 1 (2.6) | |
| N2 | 0 | 4 (12.1) | 8 (20.5) |
Abbreviations: LLL, left lower lobe; LUL, left upper lobe; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe.
Excluded five cases converted to open surgery.
Two cases with solitary brain metastasis received brain irradiation before lobectomy.
Excluded cases with benign lesions.
Two cases with solitary brain metastasis received brain irradiation before lobectomy. Pleural dissemination was found during surgery in one case.
Fisher's exact test.
Comparison of perioperative outcomes between different phases, N = 95 (±s)
| Outcomes | Phase 1 ( | Phase 2 ( | Phase 3 ( | Total (N = 95) |
|
|---|---|---|---|---|---|
| Total operative time | 181.7 ± 60.1 | 133.85 ± 52.5 | 116.1 ± 46.6 | 130.6 ± 53.8 | 0.001 |
| Console time | 140.7 ± 53.9 | 96.4 ± 53.0 | 84.4 ± 46.3 | 95.5 ± 52.3 | 0.001 |
| Docking time (min) | 9.5 ± 5.2 | 5.7 ± 2.4 | 6.2 ± 2.4 | 6.3 ± 3.0 | 0.026 |
| Blood loss (ml) | 93.0 ± 52.1 | 80.4 ± 73.8 | 72.3 ± 64.3 | 78.0 ± 67.1 | 0.238 |
| No. of mediastinal LNs harvested | 15.7 ± 11.9 | 19.3 ± 17.3 | 17.5 ± 10.1 | 18.1 ± 13.7 | 0.743 |
| No. of total LNs harvested | 29.3 ± 12.9 | 38.2 ± 22.7 | 33.0 ± 15.3 | 34.8 ± 18.8 | 0.513 |
| Conversion | 9.1 (1/11) | 4.7 (2/43) | 4.3 (2/46) | 5.0 (5/100) | 1.000 |
| Postoperative complication, % | 10.0 (1/10) | 12.2 (5/41) | 4.5 (2/44) | 8.4 (8/95) | 1.000 |
| Atrial fibrillation | 10.0 (1/10) | 2.4 (1/41) | 2.3 (1/44) | 3.2 (3/95) | |
| Air leak >5 days | 0 | 7.3 (3/41) | 2.3 (1/44) | 2.1 (2/95) | |
| Atelectasis | 0 | 2.4 (1/41) | 0 | 3.2 (3/95) | |
| Chest tube duration (days) | 3.4 ± 0.8 | 3.9 ± 1.6 | 3.7 ± 1.2 | 3.7 ± 1.4 | 0.701 |
| Length of stay in hospital (days) | 5.0 ± 0.7 | 5.1 ± 1.5 | 4.7 ± 1.1 | 4.9 ± 1.2 | 0.490 |
| Cost (¥) | 102151.7 ± 7793.7 | 105871.2 ± 14976.7 | 107308.8 ± 9618.0 | 106145.5 ± 12080.7 | 0.254 |
Abbreviation: LNs, lymph nodes.
Excluded five cases converted to open surgery.
Compared among three phases.
Defined as the time of skin to skin.
Defined as the time of operating console.
No. of patients converted to open surgery divided by no. of total patients.
Fisher's exact test.